Abstract
Recent evidence suggests that mesenchymal stem cells (MSCs) selectively home to tumors and contribute to the formation of tumor-associated stroma. These stromal precursors can be genetically modified to produce anticancer agents in situ in tumors. The resulting local, high-level production of these agents blunts tumor growth kinetics and inhibits tumor growth. In this chapter, we will review the ability of MSCs and other bone marrow-derived cell populations to integrate into the tumor microenvironment, and their potential roles in that setting. We will also examine the biological rationale for using MSCs and other bone marrow-derived cell populations as delivery vehicles for antitumor proteins.
| Original language | English (US) |
|---|---|
| Title of host publication | Stem Cell Transplantation |
| Subtitle of host publication | Biology, Processing, and Therapy |
| Publisher | Wiley-VCH Verlag GmbH & Co. KGaA |
| Pages | 157-175 |
| Number of pages | 19 |
| ISBN (Print) | 3527310185, 9783527310180 |
| DOIs | |
| State | Published - Aug 28 2006 |
Keywords
- Clinical applications
- Genetic targeting of tumors
- MSC tumor tropism to wound healing
- Mesenchymal stem cells (MSC)
- Stem cell biology
- Transplantation
- Tumor progression
- Tumor-stroma interactions
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology